Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Nov 7;18(41):5990-3.
doi: 10.3748/wjg.v18.i41.5990.

Newly developed autoimmune cholangitis without relapse of autoimmune pancreatitis after discontinuing prednisolone

Affiliations
Case Reports

Newly developed autoimmune cholangitis without relapse of autoimmune pancreatitis after discontinuing prednisolone

Ji Hun Kim et al. World J Gastroenterol. .

Abstract

A 57-year-old man presented with a 2-wk history of painless jaundice and weight loss. He had a large ill-defined enhancing mass-like lesion in the uncinate process of the pancreas with stricture of the distal common bile duct. Aspiration cytology of the pancreatic mass demonstrated inflammatory cells without evidence of malignancy. Total serum immunoglobulin G level was slightly elevated, but IgG4 level was normal. After the 2-wk 40 mg prednisolone trial, the patient's symptoms and bilirubin level improved significantly. A follow-up computed tomography (CT) scan showed a dramatic resolution of the pancreatic lesion. A low dose steroid was continued. After six months he self-discontinued prednisolone for 3 wk, and was presented with jaundice again. A CT scan showed newly developed intrahepatic biliary dilatation and marked concentric wall thickening of the common hepatic duct and the proximal common bile duct without pancreatic aggravation. The patient's IgG4 level was elevated to 2.51 g/L. Prednisolone was started again, after which his serum bilirubin level became normal and the thickening of the bile duct was resolved. This case suggests that autoimmune pancreatitis can progress to other organs that are not involved at the initial diagnosis, even with sustained pancreatic remission.

Keywords: Autoimmune disease; Cholangitis; Pancreatitis; Prednisolone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Initial abdominal computed tomography scan revealed an ill-defined enhancing mass-like lesion in the uncinate process of the pancreas with a dilatation of common bile duct. A: The uncinate process of the pancreas (white arrow) measuring 5.7 cm × 3.2 cm with regional infiltrations; B: In addition to this, there is small amounts of fluid collections around the pancreas head (white arrows).
Figure 2
Figure 2
Magentic resonance cholangiopancreatography and endoscopic retrograde cholangiography. A: Magentic resonance cholangiopancreatography showed moderate dilatation of the intrahepatic and common bile duct. The distal common bile duct had an abrupt narrowing. The pancreatic duct was unremarkable; B: Endoscopic retrograde cholangiography revealed a beak shaped stricture of the distal common bile duct with biliary dilatation above it.
Figure 3
Figure 3
Photomicrograph of cytologic specimen obtained by endoscopic ultrasound-fine needle aspiration, showing lymphocytes (arrows) and irregular sheets of bland ductal epithelial cells on the bloody background (hematoxylin and eosin, × 400).
Figure 4
Figure 4
Follow up abdominal computed tomography scan. A: Coronal image revealed a stenosis of the common hepatic and the proximal common bile duct (white arrow) with significant thickening and inner wall enhancement of the bile duct; B: There was no pancreatic relapse (white arrow).
Figure 5
Figure 5
Abdominal computed tomography scan after retreatment with prednisolone showed resolution of the thickening of the bile duct (white arrow).

Similar articles

Cited by

References

    1. Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med. 2006;355:2670–2676. - PubMed
    1. Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, Pearson RK, Smyrk TC, Petersen BT, Topazian MD, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010;139:140–148; quiz 140-148. - PubMed
    1. Chari ST, Murray JA. Autoimmune pancreatitis, Part II: the relapse. Gastroenterology. 2008;134:625–628. - PubMed
    1. Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, Kim MH, Klöppel G, Lerch MM, Löhr M, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352–358. - PubMed
    1. Kamisawa T, Funata N, Hayashi Y. Lymphoplasmacytic sclerosing pancreatitis is a pancreatic lesion of IgG4-related systemic disease. Am J Surg Pathol. 2004;28:1114. - PubMed

Publication types

MeSH terms